CUL5 and non-small cell lung carcinoma: Specifically, UBE2F upregulation enhances the neddylation levels and CUL5 activity, thereby reinforcing CRL5-mediated degradation of NOXA and leading to platinum and etoposide resistance in non-small cell lung cancer (NSCLC) and CRC [36, 64].